Real-World Experience with<sup>177</sup>Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval
Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T. Kim, Rachelle Saelee, A. H. Morley, Roxanna Juarez, Courtney Lawhn-Heath, Yingbing Wang, Ivan de Kouchkovsky, Thomas A. Hope
Abstract
We report our initial real-world experience with <sup>177</sup>Lu-PSMA-617 radioligand therapy. <b>Methods:</b> We performed a retrospective review of patients treated with <sup>177</sup>Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated. <b>Results:</b> Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of 18 (39%) patients who did not meet the TheraP PSMA imaging criteria achieved a PSA50. Nineteen of 31 (61%) patients who did not meet the VISION laboratory criteria achieved a PSA50. Sixty-three patients had a delay or stoppage in therapy, which was due to a good response in 19 patients and progressive disease in 14 patients. Of 10 patients with a good response who restarted treatment, 9 subsequently achieved a PSA50 on retreatment. The most common toxicities were anemia (33%) and thrombocytopenia (21%). <b>Conclusion:</b> At our center, patients who did not meet the TheraP PSMA imaging criteria or the VISION laboratory criteria benefited from <sup>177</sup>Lu-PSMA-617 radioligand therapy.